Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

 

International Congress of Parkinson’s Disease and Movement Disorders ®

Congress

Parallel Session 3412

Imaging Parkinsonian Disorders in 2026: What's Next for Neuroimaging

Tuesday, October 6, 2026
14:30 - 16:00 | Conference Room North 203, Level 2

In this session, the faculty will present how imaging markers can track progression from prodromal stages to clinical Parkinson's disease. They will review the evolution of alpha-synuclein PET tracers as markers of disease-specific pathology. The role of tau and amyloid PET imaging, as well as cerebrovascular changes in Parkinson's disease will be summarized.

Chairs:

Cecilia Peralta, Argentina
A. Jon Stoessl, Canada

Presenters:

Neuroimaging Clues of Phenoconversion to Parkinson’s Disease
Jee-Young Lee, Korea

Imaging Alpha-Synuclein: The Next Generation of Imaging Tracers
Hitoshi Shimada, Japan

Imaging Tau and Co-Pathologies in Parkinsonisms: The Next Steps
Antonio Strafella, Canada

CSPC Liaison(s):

Maria Cecelia Peralta, Argentina

Learning Objectives

At the conclusion of this session, participants should be better able to:

  1. Evaluate recent evidence linking imaging markers, from prodromal stages to motor phenoconversion and disease progression
  2. Discuss the state-of-the-art of alpha synuclein imaging tracers development as well as connectome-based models in understanding alpha-synuclein spread across neuronal networks
  3. Discuss advances in the imaging of non-synuclein protein deposition in parkinsonism

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Industry
Researcher / Basic Science

Education Level

Advanced / Expert
Intermediate / Experienced